Molecular Diagonstics Market : Current Scenario and Forecast (2019-2025): Emphasis on Product (Reagents, Instruments Services), Techniques (Polymerase Chain Reaction (PCR), Transcription-Mediated Amplification (TMA), In Situ Hybridization, DNA Sequencing & Next-Generation Sequencing (NGS), Chips and Microarrays, Others), Application (Microbiology, Virology, Hospital Acquired Infections (HAI), Genetic Testing, Oncology, Pharmacogenetics, Human Leukocytes Antigen (HLA), Blood Screening, Others), End-Users (Hospitals, Clinics & Labs, Other Healthcare Facilities) and Region/Country
- UNI4065900
- 399 Pages
- December 2019
- Healthcare
In this evolving environment, it is a business imperative for diagnostic manufacturers to understand, demonstrate, and clearly articulate how their offerings can lead not only to better patient outcomes but also create value for a variety of key stakeholders. There are many ways that diagnostic technologies can impact the quality and cost of care. Medical diagnostic tests and technologies are at the forefront of health care and personalized medicine. These technologies increasingly are a key component in ensuring that the right treatment gets to the right patient at the right time. Advances in life sciences and in test technologies are making diagnostics ever more central in the delivery of effective health care. It is well understood by health care stakeholders that diagnostics significantly affect clinical decision-making. Nevertheless, it is critical for diagnostic test developers to be able to demonstrate the value of their tests to a variety of stakeholders in the face of growing scrutiny and cost pressure directed at almost every health care sector
“Reagents are the majorly used product under the Molecular Diagnostics market, holding ~69% share in 2018”
Based on product type the global molecular diagnostics market is bifurcated into Instruments, Reagents and services and others. The market of the Reagents segment is expected to grow tremendously and is projected to dominate the market in 2025 due to the high demand for over-the-counter diagnostic tests, rise in adoption of these tests in nonmedical facilities, such as home.
“Polymerase chain reaction (PCR) is expected to dominate the technique segment during the analyzed period.”
Molecular diagnostics market, based on technique is segmented into Polymerase Chain Reaction (PCR), Transcription-Mediated Amplification (TMA), In Situ Hybridization, DNA Sequencing & Next-Generation Sequencing (NGS), Chips and Microarrays and others. The PCR segment occupied the largest share and is expected to maintain its dominance throughout the forecast period 2019-2025 owing to the increased usage and advancements in PCR techniques.
“Molecular Diagnostic techniques are majorly applied for Virology study, the segment generated revenue of US$ 2,243.9 million in 2018”
The molecular diagnostics market is applied in various medical fields including Microbiology, Virology, Hospital Acquired Infections (HAI), Genetic Testing, Oncology, Pharmacogenetics, Human Leukocytes Antigen (HLA), Blood Screening and others. In 2018, Virology segment dominated the market and is anticipated to dominate this segment in 2025. However, Oncology application segment is expected to witness highest CAGR growth during the forecast period 2019-2025.
“Amongst end-users’ type, hospitals are anticipated to dominate Global Molecular Diagnostics market by 2025.”
Hospitals, clinics & labs and others are the major end-users of the molecular diagnostic technology. In 2018, the application of the technology was dominated by Hospitals segment. The increased adoption in hospitals is driven by high procedure volume and extensive presence of ancillary support in terms of manpower and infrastructure. However, Clinics & labs application type is expected to witness reasonable CAGR growth during the analyzed period.
“North America dominated the market for molecular diagnostic technology in 2018, followed by Asia-Pacific and Europe”
For a deep-dive analysis of the industry, detailed regional/country-level analysis is conducted for markets including North America (US, Canada, Rest of US), Europe (Germany, France, Spain, Italy, UK, Rest of Europe), Asia-Pacific (China, Japan, India, Australia and Rest of Asia-Pacific) and Rest of World (Brazil and Other Rest of World). In 2018, North America generated revenue of US$ 2,964.9 million, however, Asia-Pacific is expected to witness highest CAGR of 6.74%b during the forecast period. The dominance of North America is majorly driven by the presence of a well-established diagnostic infrastructure, technological advancements, patient awareness and presence of advanced products in the field of molecular diagnostics.
Competitive Landscape-Top 10 Market Players
Abbott Laboratories, Becton Dickinson and Company, Biomerieux SA, Danaher Corporation, Hologic, Inc., Qiagen, Roche, Siemens Healthineers AG, Sysmex Corporation and Thermo Fisher Scientific are some of the prominent players operating in the Global Molecular Diagnostics market industry. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Reasons to buy:
• Current and future market size from 2018 to 2025 in terms of value (US$)
• Combined analysis of deep-dive secondary research and input from primary research through Key Opinion Leaders of the industry
• Country-level details of the overall adoption of molecular diagnostics market
• A quick review of overall industry performance at a glance
• In-depth analysis of key industry players
• A detailed analysis of regulatory framework, drivers, restraints, key trends and opportunities prevailing in the industry
• Examination of industry attractiveness with the help of Porter’s Five Forces analysis and start-ups
• The study comprehensively covers the market across different segments and sub-segments of the technology
• Regions/countries Covered: North America (US, Canada, Rest of US), Europe (Germany, France, Spain, Italy, UK, Rest of Europe), Asia-Pacific (China, Japan, India, Australia and Rest of Asia-Pacific) and Rest of World (Brazil and Other Rest of World)
Customization Options:
UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients. The Global Molecular Diagnostics Market can be customized to the country level or any other market segment.
1.1 Market Definition 21
1.2 Objective of the Study 21
1.3 Limitation 22
1.4 Stakeholders 22
1.5 Currency used in the Report 22
1.6 Scope of the Global Molecular Diagnostics Market Study 23
2. RESEARCH METHODOLOGY 24
2.1 Research Methodology for Global Molecular Diagnostics (MDx) Market Study 24
2.1.1 Main objective of the Global Molecular Diagnostics Market Study 25
3. COMPREHENSIVE ASSESSMENT OF THE VALUE OF DIAGNOSTIC TESTS 26
3.1 General Overview 26
3.2 Capturing the full spectrum of the value that a diagnostic test contributes 29
3.3 Ensuring that robust analyses underpin the value assessment 31
3.4 Accounting for variation in diagnostic test types in value assessment methods 32
3.5 Aligning on how to define and measure value drivers 34
3.5.1 Value Driver: Clinical Impact 34
3.5.2 Value Driver: Non-Clinical Patient Impact 36
3.5.3 Value Driver: Care Delivery Revenue and Cost Impact 37
3.5.4 Value Driver: Public/Population Impact 39
4. REFRAMING THE DIAGNOSTICS INDUSTRY 41
4.1 General Overview 41
5. EXECUTIVE SUMMARY 44
6. INDUSTRY PERFORMANCE 47
7. RISK MITIGATION 48
7.1 General Overview 48
7.2 Supply Chain 49
7.3 Risk Assessment 50
7.4 Bulk, Custom and Contract Manufacturing 51
5. MARKET OVERVIEW 52
5.1 Introduction of Molecular Diagnostics Market 52
5.1.1 Essential Components or Attributes of Diagnostics 54
5.1.2 Main Categories of Diagnostics 55
5.1.3 Settings of Use 57
5.2 Current and Future Use of Diagnostic Products 58
5.2.1 Primary Uses of Diagnostics 58
5.2.1.1 Predictive Applications/Screening/Early Disease Detection 59
5.2.1.2 Diagnostic 59
5.2.1.3 Secondary Risk Assessment – Prognostic 60
5.2.1.4 Drug Selection/Treatment Targeting 60
5.2.1.5 Disease/Condition Monitoring and Management 60
5.2.2 Molecular Diagnostics: Overview of Future Trends and Directions 60
5.2.2.1 Predict Disease Before Symptoms Appear 60
5.2.2.2 Predict Beneficial and Adverse Treatment Effects 61
5.2.2.3 Enable Personalized “Real-Time” Treatment and Disease Management Regimens 63
5.2.2.4 Facilitate Point-of-care and Near-patient Testing 64
5.2.2.5 Enable Home Testing 64
5.2.2.6 Public Health, Environmental, Bioterrorism Applications 65
5.2.2.7 Technology and Testing System Integration 66
5.2.3 The Importance of Molecular Diagnostics 67
5.2.4 Market Drivers 68
5.2.4.1 Increasing Prevalence of Chronic Diseases 68
5.2.4.2 Rising Geriatric Population 70
5.2.4.3 Increasing adoption of Point-of-Care Diagnosis 71
5.2.4.4 Technology Advancement in the In-Vitro Diagnostics 73
5.2.4.5 Advances in Genomics and Proteomics 74
5.2.5 Market Restraints 75
5.2.5.1 Unfavorable Reimbursement Policies for In-Vitro Diagnostics 75
5.2.5.2 High Prices of Molecular Diagnostics Tests 76
5.2.6 Market Opportunities 76
5.2.6.1 Increasing Support from Governments and Key Players 76
5.2.6.2 Growing Significance of Companion Diagnostics 78
5.2.7 Market Trends 80
5.2.7.1 Changing Reimbursement Models and Regulations 80
5.2.7.2 Investing in Unifying Technology 81
5.2.7.3 Consolidation and Automation of Labs 82
5.2.7.4 Shift to Data-Driven Healthcare 83
5.2.7.5 Consumer Lab Testing 83
5.2.7.6 Healthcare Convergence 84
6. REGULATIONS AND REIMBURSEMENT POLICY 86
6.1 Regulation 86
6.1.1 United States 86
6.1.1.1 Approval/Clearance of Molecular Diagnostic Instruments 86
6.1.1.2 Recommendations for Submissions for Molecular Diagnostic Instruments with Combined Functions 88
6.1.1.2.1 New Instruments 88
6.1.1.2.2 Existing Approved/Cleared Instruments 88
6.1.1.2.3 Submission Information, Labeling, and Marketing 88
6.1.1.2.4 Promotion and Labeling Issues 89
6.1.1.2.5 Software/Hardware Changes 89
6.1.1.2.6 Third-Party Assay Developers 90
6.1.1.2.7 MDR Reporting 90
6.2 Reimbursement 91
7. KEY MARKET INDICATORS 96
7.1 Demand Side Analysis 96
7.1.1 Some of the Key Facts about Aging Population 97
7.1.2 Health Conditions Associated with Aging 98
7.1.2.1 Some of the key facts about Cardiovascular Diseases (CVD) as per WHO 99
7.2 Supply Side Analysis 100
7.2.1 Product Launches 102
7.2.2 Partnership 108
7.2.3 Business Expansions and Investments 112
7.2.4 Merger and Acquisition 114
7.3 SWOT Analysis of Molecular Diagnostics 116
7.4 Value Chain Analysis of Molecular Diagnostics 117
8. MARKET INSIGHT BY PRODUCT 118
8.1 General Overview 118
8.1.1 Reagents 120
8.1.2 Instruments Services 126
9. MARKET INSIGHT BY TECHNIQUE 131
9.1 General Overview 131
9.1.1 Polymerase chain reaction (PCR) 133
9.1.2 Transcription-Mediated Amplification (TMA) 136
9.1.3 In Situ Hybridization & FISH 137
9.1.4 DNA Sequencing & Next-Generation Sequencing (NGS) 138
9.1.5 Case Study: Next Generation Sequencing for Clinical Diagnostics 139
9.1.6 Chips and Microarrays 142
9.1.7 Others 144
10. MARKET INSIGHT BY APPLICATION 146
10.1 General Overview 146
10.1.1 Microbiology 147
10.1.2 Virology 148
10.1.3 Hospital Acquired Infections (HAI) 153
10.1.4 Genetic Testing 155
10.1.5 Oncology 156
10.1.6 Pharmacogenetics 160
10.1.7 Human Leukocyte Antigen (HLA Testing) 161
10.1.8 Blood Screening 163
10.1.9 Others 164
11. MARKET INSIGHT BY END USER 166
11.1 General Overview 166
11.1.1 Hospitals 167
11.1.2 Clinics & Laboratory 168
11.1.3 Others 173
12. MARKET INSIGHT BY REGION 175
12.1 General Overview 175
12.2 North America MDx Market Insight 177
12.2.1 North America Molecular Diagnostics Market by Product 178
12.2.2 North America Molecular Diagnostics Market by Technique 178
12.2.3 North America Molecular Diagnostics Market by Application 179
12.2.4 North America Molecular Diagnostics Market by End Users 179
12.2.5 North America Molecular Diagnostics Market by Country 180
12.2.5.1 United States 180
12.2.5.1.1 Key Findings on Healthcare Spending in the US, 2017 181
12.2.5.1.2 US Health Spending by Type of Service or Product, 2017 181
12.2.5.1.3 Health Spending by Major Sources of Funds 182
12.2.5.1.4 United States Molecular Diagnostics Market by Product 184
12.2.5.1.5 United States Molecular Diagnostics Market by Technique 184
12.2.5.1.6 United States Molecular Diagnostics Market by Application 185
12.2.5.1.7 United States Molecular Diagnostics Market by End Users 185
12.2.5.2 Canada 186
12.2.5.2.1 Key Findings on Canada Healthcare Spending, 2018 187
12.2.5.2.2 Key Findings on Hospital sector Spending in Canada, 2017 188
12.2.5.2.3 Canada Molecular Diagnostics Market by Product 189
12.2.5.2.4 Canada Molecular Diagnostics Market by Technique 190
12.2.5.2.5 Canada Molecular Diagnostics Market by Application 190
12.2.5.2.6 Canada Molecular Diagnostics Market by End Users 191
12.2.5.3 Rest of North America 191
12.2.5.3.1 Rest of NA Molecular Diagnostics Market by Product 192
12.2.5.3.2 Rest of NA Molecular Diagnostics Market by Technique 193
12.2.5.3.3 Rest of NA Molecular Diagnostics Market by Application 193
12.2.5.3.4 Rest of NA Molecular Diagnostics Market by End Users 194
12.3 Europe Molecular Diagnostics Market Insight 194
12.3.1 Europe Molecular Diagnostics Market by Product 195
12.3.2 Europe Molecular Diagnostics Market by Technique 196
12.3.3 Europe Molecular Diagnostics Market by Application 196
12.3.4 Europe Molecular Diagnostics Market by End Users 197
12.3.5 Europe Molecular Diagnostics Market by Country 197
12.3.5.1 Germany 198
12.3.5.1.1 Germany Molecular Diagnostics Market by Product 199
12.3.5.1.2 Germany Molecular Diagnostics Market by Technique 200
12.3.5.1.3 Germany Molecular Diagnostics Market by Application 200
12.3.5.1.4 Germany Molecular Diagnostics Market by End Users 201
12.3.5.2 France 201
12.3.5.2.1 France Molecular Diagnostics Market by Product 202
12.3.5.2.2 France Molecular Diagnostics Market by Technique 203
12.3.5.2.3 France Molecular Diagnostics Market by Application 203
12.3.5.2.4 France Molecular Diagnostics Market by End Users 204
12.3.5.3 Spain 204
12.3.5.3.1 Spain Molecular Diagnostics Market by Product 206
12.3.5.3.2 Spain Molecular Diagnostics Market by Technique 206
12.3.5.3.3 Spain Molecular Diagnostics Market by Application 207
12.3.5.3.4 Spain Molecular Diagnostics Market by End Users 207
12.3.5.4 Italy 208
12.3.5.4.1 Italy Molecular Diagnostics Market by Product 209
12.3.5.4.2 Italy Molecular Diagnostics Market by Technique 209
12.3.5.4.3 Italy Molecular Diagnostics Market by Application 210
12.3.5.4.4 Italy Molecular Diagnostics Market by End Users 210
12.3.5.5 United Kingdom 211
12.3.5.5.1 United Kingdom Molecular Diagnostics Market by Product 213
12.3.5.5.2 United Kingdom Molecular Diagnostics Market by Technique 213
12.3.5.5.3 United Kingdom Molecular Diagnostics Market by Application 214
12.3.5.5.4 United Kingdom Molecular Diagnostics Market by End Users 214
12.3.5.6 Rest of Europe 215
12.3.5.6.1 Rest of Europe Molecular Diagnostics Market by Product 216
12.3.5.6.2 Rest of Europe Molecular Diagnostics Market by Technique 217
12.3.5.6.3 Rest of Europe Molecular Diagnostics Market by Application 217
12.3.5.6.4 Rest of Europe Molecular Diagnostics Market by End Users 218
12.4 Asia-Pacific Molecular Diagnostics Market Insight 218
12.4.1 Asia-Pacific Molecular Diagnostics Market by Product 219
12.4.2 Asia-Pacific Molecular Diagnostics Market by Technique 220
12.4.3 Asia-Pacific Molecular Diagnostics Market by Application 220
12.4.4 Asia-Pacific Molecular Diagnostics Market by End Users 221
12.4.5 Asia-Pacific Molecular Diagnostics Market by Country 221
12.4.5.1 China 222
12.4.5.1.1 China In-Vitro Diagnostics Services Market 223
12.4.5.1.2 China Molecular Diagnostics Market by Product 223
12.4.5.1.3 China Molecular Diagnostics Market by Technique 224
12.4.5.1.4 China Molecular Diagnostics Market by Application 224
12.4.5.1.5 China Molecular Diagnostics Market by End Users 225
12.4.5.2 India 225
12.4.5.2.1 India Molecular Diagnostics Market by Product 227
12.4.5.2.2 India Molecular Diagnostics Market by Technique 228
12.4.5.2.3 India Molecular Diagnostics Market by Application 228
12.4.5.2.4 India Molecular Diagnostics Market by End Users 229
12.4.5.3 Japan 229
12.4.5.3.1 Japan Molecular Diagnostics Market by Product 231
12.4.5.3.2 Japan Molecular Diagnostics Market by Technique 232
12.4.5.3.3 Japan Molecular Diagnostics Market by Application 232
12.4.5.3.4 Japan Molecular Diagnostics Market by End Users 233
12.4.5.4 Australia 233
12.4.5.4.1 Australia Molecular Diagnostics Market by Product 235
12.4.5.4.2 Australia Molecular Diagnostics Market by Technique 236
12.4.5.4.3 Australia Molecular Diagnostics Market by Application 236
12.4.5.4.4 Australia Molecular Diagnostics Market by End Users 237
12.4.5.5 Rest of APAC Market Insight 237
12.4.5.5.1 Rest of APAC Molecular Diagnostics Market by Product 239
12.4.5.5.2 Rest of APAC Molecular Diagnostics Market by Technique 239
12.4.5.5.3 Rest of APAC Molecular Diagnostics Market by Application 240
12.4.5.5.4 Rest of APAC Molecular Diagnostics Market by End Users 240
12.5 Rest of World Market Insight 241
12.5.1 Rest of World Molecular Diagnostics Market by Product 242
12.5.2 Rest of World Molecular Diagnostics Market by Technique 242
12.5.3 Rest of World Molecular Diagnostics Market by Application 243
12.5.4 Rest of World Molecular Diagnostics Market by End Users 243
12.5.5 Rest of World Molecular Diagnostics Market by Country 244
12.5.5.1 Brazil 244
12.5.5.1.1 Brazil Molecular Diagnostics Market by Product 246
12.5.5.1.2 Brazil Molecular Diagnostics Market by Technique 246
12.5.5.1.3 Brazil Molecular Diagnostics Market by Application 247
12.5.5.1.4 Brazil Molecular Diagnostics Market by End Users 247
12.5.5.2 Other Rest of World 248
12.5.5.2.1 Other Rest of World Molecular Diagnostics Market by Product 248
12.5.5.2.2 Other Rest of World Molecular Diagnostics Market by Technique 249
12.5.5.2.3 Other Rest of World Molecular Diagnostics Market by Application 249
12.5.5.2.4 Other Rest of World Molecular Diagnostics Market by End Users 250
13. COMPETITIVE SCENARIO 251
13.1 Porter’s Five forces analysis 251
13.1.1 Bargaining Power of Suppliers 252
13.1.2 Bargaining Power of Buyers 252
13.1.3 Threat of New Entrants 253
13.1.4 Threat of Substitutes 254
13.1.5 Industry Rivalry 254
13.2 Market Share Analysis, by Company 255
13.2.1 Molecular Diagnostics Market Share Analysis by Company 2018 255
14. TOP COMPANY PROFILES 258
14.1 Abbott Laboratories 258
14.1.1 Key Facts 258
14.1.2 Business Description 258
14.1.3 Key Product/Services Offerings 259
14.1.4 Growth Strategy 259
14.1.5 SWOT Analysis 260
14.1.6 Key Financials 261
14.1.6.1 Revenue Split 262
14.1.7 Recent Developments 262
14.1.7.1 Product Launches 262
14.1.7.2 Partnership 263
14.1.7.3 Merger and Acquisition 263
14.2 Becton, Dickinson and Company 264
14.2.1 Key Facts 264
14.2.2 Business Description 264
14.2.3 Key Product/Services Offerings (AI Technology) 264
14.2.4 Growth Strategy 265
14.2.5 SWOT Analysis 266
14.2.6 Key Financials 267
14.2.6.1 Revenue Split 268
14.2.7 Recent Developments 268
14.2.7.1 Product Launches 268
14.2.7.2 Business Expansions and Investments 269
14.2.7.3 Merger & Acquisitions 270
14.3 Biomérieux SA 271
14.3.1 Key Facts 271
14.3.2 Business Description 271
14.3.3 Key Product/Services Offerings 272
14.3.4 Growth Strategy 272
14.3.5 SWOT Analysis 273
14.3.6 Key Financials 274
14.3.6.1 Revenue Split 275
14.3.7 Recent Developments 275
14.3.7.1 Product Launches 275
14.3.7.2 Partnerships 276
14.3.7.3 Mergers and Acquisitions 277
14.4 Hologic, Inc. 278
14.4.1 Key Facts 278
14.4.2 Business Description 278
14.4.3 Key Product/Services Offerings 279
14.4.4 Growth Strategy 281
14.4.5 SWOT Analysis 281
14.4.6 Key Financials 282
14.4.6.1 Revenue Split 283
14.4.7 Recent Developments 283
14.4.7.1 Product Launches 283
14.4.7.2 Partnerships 285
14.4.7.3 Business Expansion & Investment 286
14.4.7.4 Mergers and Acquisitions 286
14.5 Danaher Corporation 287
14.5.1 Key Facts 287
14.5.2 Business Description 287
14.5.3 Key Product/Services Offerings 287
14.5.4 Growth Strategy 288
14.5.5 SWOT Analysis 289
14.5.6 Key Financials 290
14.5.6.1 Revenue Split 291
14.5.7 Recent Developments 291
14.5.7.1 Merger and Acquisitions 291
14.6 Qiagen 292
14.6.1 Key Facts 292
14.6.2 Business Description 292
14.6.3 Key Product/Services Offerings 293
14.6.4 Growth Strategy 293
14.6.5 Key Milestones 294
14.6.6 SWOT Analysis 294
14.6.7 Key Financials 295
14.6.7.1 Revenue Split 296
14.6.8 Recent Developments 296
14.6.8.1 Product Launches 296
14.6.8.2 Partnerships 297
14.6.8.3 Business Expansions and Investment 299
14.6.8.4 Mergers and Acquisitions 300
14.7 Roche Holding AG 301
14.7.1 Key Facts 301
14.7.2 Business Description 301
14.7.3 Key Product/Services Offerings 302
14.7.4 Growth Strategy 302
14.7.5 SWOT Analysis 303
14.7.6 Key Financials 304
14.7.6.1 Revenue Split 305
14.7.7 Recent Developments 305
14.7.7.1 Product Launches 305
14.7.7.2 Partnership 307
14.7.7.3 Mergers and Acquisitions 307
14.8 Siemens Healthineers AG 308
14.8.1 Key Facts 308
14.8.2 Business Description 308
14.8.3 Key Product/Services Offerings 309
14.8.4 Growth Strategy 309
14.8.5 SWOT Analysis 310
14.8.6 Key Financials 311
14.8.6.1 Revenue Split 312
14.8.7 Recent Developments 312
14.8.7.1 Product Launches 312
14.8.7.2 Partnership 313
14.8.7.3 Business Expansion and Investment 313
14.8.7.4 Merger and Acquisitions 313
14.9 Thermo Fisher Scientific 314
14.9.1 Key Facts 314
14.9.2 Business Description 314
14.9.3 Key Product/Services Offerings 315
14.9.4 Growth Strategy 317
14.9.5 SWOT Analysis 317
14.9.6 Key Financials 318
14.9.6.1 Revenue Split 319
14.9.7 Recent Developments 319
14.9.7.1 Product Launch 319
14.9.7.2 Partnerships 322
14.9.7.3 Expansion and Investment 323
14.9.7.4 Merger and Acquisition 324
14.10 Sysmex Corporation 326
14.10.1 Key Facts 326
14.10.2 Business Description 326
14.10.3 Key Product/Services Offerings 326
14.10.4 Growth Strategy 327
14.10.5 SWOT Analysis 328
14.10.6 Key Financials 329
14.10.6.1 Revenue Split 330
14.10.7 Recent Developments 330
14.10.7.1 Product Launches 330
14.10.7.2 Partnership 331
14.10.7.3 Business Expansion & Investments 332
14.10.7.4 Merger and Acquisitions 333
TABLE 2 Considerations in Demonstrating Value by Diagnostic Test Type 33
TABLE 3 Value Driver: Clinical Impact 34
TABLE 4 Value Driver: Non-Clinical Patient Impact 36
TABLE 5 Value Driver: Care Delivery Revenue and Cost Impact 38
TABLE 6 Value Driver: Public/Population Impact 39
TABLE 7 Risk from Raw Material Supply and In-House Manufacturing Capabilities of MDx Manufacturers 48
TABLE 8 Examples of Molecular Diagnostics across the Continuum of Care 53
TABLE 9 Categories and Examples of Diagnostic Products 56
TABLE 10 Rapidly Expanding Areas of Scientific Inquiry 61
TABLE 11 Number and distribution of persons aged 60 years or over by region, in 2017 and 2050 71
TABLE 12 Presently Used Proteomics Tools in Diseases Diagnostics 75
TABLE 13 Oncology CDx Market: Selected Tests Resulting from Partnerships, U.S., 2017 79
TABLE 14 MDx Market Regulatory Analysis, Selected Regions 81
TABLE 15 CEN/TS and ISO standards on the pre-examination process for Molecular Diagnostics that have emerged from SPIDIA 91
TABLE 16 Product Launches 102
TABLE 17 Partnership 108
TABLE 18 Business Expansions and Investments 112
TABLE 19 Merger and Acquisition 114
TABLE 20 Products List for In-Vitro Diagnostics Reagents 124
TABLE 21 IVD Ancillary Reagents 125
TABLE 22 IVD Market Regulatory Analysis, Selected Regions 127
TABLE 23 Overview of Next-Generation Sequencing Technologies 139
TABLE 24 Microarrays and Applications 143
TABLE 25 Global Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 147
TABLE 26 Standardised Molecular Protocols in Diagnostic Virology 149
TABLE 27 Examples of Molecular Diagnostics in Cancer 157
TABLE 28 General Molecular Diagnostics for Primary Health Care 169
TABLE 29 General Molecular Diagnostics for health care facilities with clinical laboratories 170
TABLE 30 Countries with Shift in Average Life Expectancies in 2030 175
TABLE 31 North America Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 179
TABLE 32 United States Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 185
TABLE 33 Canada Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 190
TABLE 34 Rest of NA Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 193
TABLE 35 Europe Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 196
TABLE 36 Germany Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 200
TABLE 37 France Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 203
TABLE 38 Spain Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 207
TABLE 39 Italy Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 210
TABLE 40 United Kingdom Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 214
TABLE 41 Rest of Europe Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 217
TABLE 42 Asia-Pacific Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 220
TABLE 43 China Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 224
TABLE 44 India Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 228
TABLE 45 Japan Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 232
TABLE 46 Australia, Total Health Expenses, US$ Million 235
TABLE 47 Australia Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 236
TABLE 48 Rest of APAC Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 240
TABLE 49 Rest of World Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 243
TABLE 50 Brazil Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 247
TABLE 51 Other Rest of World Molecular Diagnostics Market Size, by Application, 2018-25 (US$ Mn) 249
TABLE 52 Abbott Laboratories Key Facts 258
TABLE 53 Product segmentation of Abbott Laboratories 259
TABLE 54 Abbott laboratories Growth Strategy 259
TABLE 55 Abbott Laboratories, Inc. Product Launches 262
TABLE 56 Abbott Laboratories, Inc. Partnership 263
TABLE 57 Abbott Laboratories, Inc. Merger and Acquisition 263
TABLE 58 Becton, Dickinson and Company Key Facts 264
TABLE 59 Becton, Dickinson and Company Growth Strategy 264
TABLE 60 Becton, Dickinson and Company Growth Strategy 265
TABLE 61 Becton, Dickinson and Company Product Launches 268
TABLE 62 Becton, Dickinson and Company Business Expansions and Investments 269
TABLE 63 Becton, Dickinson and Company Merger & Acquisitions 270
TABLE 64 Biomérieux SA Key Facts 271
TABLE 65 Product segmentation of Biomérieux SA 272
TABLE 66 Biomérieux SA Growth Strategy 272
TABLE 67 Biomérieux SA Product Launches 275
TABLE 68 Biomérieux SA Partnerships 276
TABLE 69 Biomérieux SA Mergers and Acquisitions 277
TABLE 70 Hologic, Inc. Key Facts 278
TABLE 71 Hologic, Inc. Ownership Structure 278
TABLE 72 Product segmentation of Hologic, Inc. 279
TABLE 73 Hologic, Inc. Growth Strategy 281
TABLE 74 Hologic, Inc. Product Launches 283
TABLE 75 Hologic, Inc. Partnerships 285
TABLE 76 Hologic, Inc. Business Expansion & Investment 286
TABLE 77 Hologic, Inc. Merger and Acquisitions 286
TABLE 78 Danaher Corporation Key Facts 287
TABLE 79 Product Segmentation of Danaher Corporation 287
TABLE 80 Danaher Corporation Growth Strategy 288
TABLE 81 Danaher Corporation Merger and Acquisitions 291
TABLE 82 Qiagen Key Facts 292
TABLE 83 Qiagen. Ownership Structure 292
TABLE 84 Product Segmentation of Qiagen 293
TABLE 85 Qiagen Growth Strategy 293
TABLE 86 Qiagen Product Launches 296
TABLE 90 Roche Key Facts 301
TABLE 91 The product segmentation of Roche 302
TABLE 92 Roche Growth Strategy 302
TABLE 93 Roche Product Launches 305
TABLE 94 Roche Partnership 307
TABLE 95 Roche Mergers and Acquisitions 307
TABLE 96 Siemens Healthineers AG Key Facts 308
TABLE 97 Product Segmentation of Siemens Healthineers AG 309
TABLE 98 Siemens Healthineers AG Growth Strategy 309
TABLE 99 Siemens Healthineers AG Product Launches 312
TABLE 100 Siemens Healthineers AG Partnership 313
TABLE 101 Siemens Healthineers AG Business Expansion and Investment 313
TABLE 102 Siemens Healthineers AG Merger and Acquisitions 313
TABLE 103 Thermo Fisher Scientific Key Facts 314
TABLE 104 Product Segmentation of Thermo Fisher Scientific 315
TABLE 105 Thermo Fisher Scientific Growth Strategy 317
TABLE 106 Thermo Fisher Scientific Product Launch 319
TABLE 107 Thermo Fisher Scientific Partnerships 322
TABLE 108 Thermo Fisher Scientific Business Expansion and Investments 323
TABLE 109 Thermo Fisher Scientific Merger and Acquisition 324
TABLE 110 Sysmex Corporation Key Facts 326
TABLE 111 Product segmentation of Sysmex Corporation 326
TABLE 112 Sysmex Corporation Growth Strategy 327
TABLE 113 Sysmex Corporation Product Launches 330
TABLE 114 Sysmex Corporation Partnership 331
TABLE 115 Sysmex Corporation Business Expansion & Investments 332
TABLE 116 Sysmex Corporation Merger and Acquisitions 333
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
